

Multiplex Assays Market by Product & Service (Consumables, Instruments, Software & Services), Type (Nucleic Acid, Protein), Technology (Flow Cytometry, Luminescence), Application (R&D, Diagnosis), End User (Pharma, Hospitals) - Global Forecast to 2027

<https://marketpublishers.com/r/MF6BEECD290EN.html>

Date: May 2023

Pages: 200

Price: US\$ 4,950.00 (Single User License)

ID: MF6BEECD290EN

Abstracts

The multiplex assays market is valued at an estimated USD 3.5 billion in 2022 and is projected to reach USD 5.3 billion by 2027, at a CAGR of 8.8% during the forecast period. The burden of chronic diseases has necessitated the use of multiplex assays for containment and management. As many biomarkers are being discovered and validated, there is a higher probability of the development of new diagnostic tests. At present, there are only a few multiplex assays targeting specific disease classes. With the development of new biomarkers, new multiplex assays can be developed. Owing to this, biomarker validation can create opportunities for the development of the multiplex assays market. However, high instrument cost is a major factor limiting the wider adoption of multiplex assays.

“The consumables segment accounted for the highest growth rate in the multiplex assays market, by product & service, during the forecast period”

Based on product & service, the multiplex assays market is segmented into three broad categories, namely, consumables, instruments, and software & services. In 2022, the consumables segment accounted for the largest share of the market. This segment is also expected to grow at the highest CAGR. The instruments segment accounted for the second largest share of the multiplex assays market. The increasing incidence of infectious diseases & cancer, growing demand for automated and advanced

instruments with high-throughput capacities and increasing need for faster and more accurate test results with minimal human intervention are driving the instruments market segment.

“The research & development segment accounted for the highest growth rate in the multiplex assays market, by application, during the forecast period”

Based on applications, the multiplex assays market is segmented into research & development (drug discovery & development and biomarker discovery & validation) and clinical diagnostics (infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, nervous system disorders, metabolism & endocrinology disorders, and other diseases). The research & development application segment accounted the largest share of the multiplex assays market in 2022. The drug discovery & development segment accounted for the largest share of the multiplex assays market for research & development in 2022. The demand for multiplex assays in drug discovery & development has increased due to their benefits. These assays tend to be effective in evaluating drug response biomarkers, immunotherapy success, and toxicity during the clinical stages of drug development.

“Asia Pacific: The fastest-growing region multiplex assays market”

The global multiplex assays market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period. The Asia Pacific market is expected to witness the highest growth during the forecast period due to factors such as growing government efforts to increase awareness about the early detection of diseases and the increasing number of regular health check-ups; rising healthcare expenditure; the increasing number of hospitals and clinical diagnostic laboratories in India and China; and growing strength in the research base for diagnostic procedures across India, China, and Japan.

The break-up of the profile of primary participants in the multiplex assays market:

By Company Type: Tier 1 - 42%, Tier 2 - 37%, and Tier 3 - 21%

By Designation: C-level - 34%, D-level - 42%, and Others - 24%

By Region: North America - 32%, Europe - 30%, Asia Pacific - 24%, and the Rest of the World – 14%

The key players in this market are Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), DiaSorin S.p.A. (Italy), QIAGEN N.V. (Netherlands), Abcam plc (UK), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Quanterix (US), Bio-Techne (US), MESO SCALE DIAGNOSTICS, LLC (US), Randox Laboratories Ltd. (UK), Olink (Sweden), Seegene Inc. (South Korea), Siemens Healthcare AG (Germany), PerkinElmer Inc. (US), Shimadzu Corporation (Japan), Promega Corporation (US), Enzo Biochem Inc. (US), Cayman Chemical (US), Boster Biological Technology (US), Antigenix America, Inc. (US), Quansys Biosciences Inc. (US), and RayBiotech Life, Inc. (US).

Research Coverage:

This research report categorizes the multiplex assays market by product & service (consumables, instruments, and software & services), type (protein multiplex assays [planar protein assays, bead-based protein assays, and other protein assays], nucleic acid multiplex assays [planar nucleic acid assays, bead-based nucleic acid assays, and other nucleic acid assays], and cell-based Multiplex Assays), technology (flow cytometry, fluorescence detection, luminescence, multiplex real-time PCR, and other technologies), application (research & development [drug discovery & development and biomarker discovery & validation] and clinical diagnostics [infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, nervous system disorders, and metabolism & endocrinology disorders, and other diseases]), end user (pharmaceutical & biotechnology companies, hospitals & research institutes, reference laboratories, and other end users), and region (North America, Europe, Asia Pacific, and the Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the multiplex assays market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; acquisitions, agreements. new product & service launches, and recent developments associated with the multiplex assays market. Competitive analysis of upcoming startups in the multiplex assays market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall multiplex assays market and the subsegments. This report will help stakeholders understand the

competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

Analysis of key drivers (increasing use of multiplex assays in companion diagnostics, increasing advantages over singleplex and traditional assays, and increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis), restraints (rising costs of equipment and growing number of stringent regulations and standards), opportunities (increasing validation of biomarkers in molecular and protein diagnostics and rising need for high-throughput and automated systems), and challenges (increasing dearth of skilled professionals) influencing the growth of the multiplex assays market

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the multiplex assays market.

Market Development: Comprehensive information about lucrative markets – the report analyses the multiplex assays market across varied regions.

Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the multiplex assays market

Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), DiaSorin S.p.A. (Italy), and Merck KGaA (Germany) among others in the multiplex assays market strategies.

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
 - 1.2.1 INCLUSIONS & EXCLUSIONS
- 1.3 STUDY SCOPE
 - 1.3.1 REGIONAL SCOPE
 - 1.3.2 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 UNITS CONSIDERED
- 1.6 LIMITATIONS
- 1.7 STAKEHOLDERS
- 1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
- 2.2 RESEARCH APPROACH
 - FIGURE 1 MULTIPLEX ASSAYS MARKET: RESEARCH DESIGN METHODOLOGY
 - 2.2.1 SECONDARY DATA
 - 2.2.1.1 Key data from secondary sources
 - 2.2.2 PRIMARY DATA
 - 2.2.2.1 Primary sources
 - 2.2.2.2 Key data from primary sources
 - 2.2.2.3 Key industry insights
 - 2.2.2.4 Breakdown of primary interviews
 - FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
 - FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
- 2.3 MARKET SIZE ESTIMATION
 - 2.3.1 BOTTOM-UP APPROACH
 - 2.3.1.1 Approach 1: Company revenue estimation approach
 - FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
 - 2.3.1.2 Approach 2: Presentations of companies and primary interviews
 - 2.3.1.3 Growth forecast

2.3.1.4 CAGR projections

FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS

2.3.2 TOP-DOWN APPROACH

FIGURE 6 MULTIPLEX ASSAYS MARKET: TOP-DOWN APPROACH

2.4 MARKET BREAKDOWN & DATA TRIANGULATION

FIGURE 7 DATA TRIANGULATION

2.5 MARKET SHARE ANALYSIS

2.6 STUDY ASSUMPTIONS

2.7 LIMITATIONS

2.8 GROWTH RATE ASSUMPTIONS

2.9 RISK ASSESSMENT

2.9.1 RISK ASSESSMENT: MULTIPLEX ASSAYS MARKET

2.10 RECESSION IMPACT

3 EXECUTIVE SUMMARY

FIGURE 8 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)

FIGURE 9 MULTIPLEX ASSAYS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)

FIGURE 10 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)

FIGURE 11 MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)

FIGURE 12 MULTIPLEX ASSAYS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)

FIGURE 13 MULTIPLEX ASSAYS MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)

4 PREMIUM INSIGHTS

4.1 MULTIPLEX ASSAYS MARKET OVERVIEW

FIGURE 14 INCREASING ADOPTION OF MULTIPLEX ASSAYS IN COMPANION DIAGNOSTICS TO DRIVE MARKET GROWTH

4.2 MULTIPLEX ASSAYS MARKET SHARE, BY PRODUCT & SERVICE, 2022 VS. 2027

FIGURE 15 CONSUMABLES PRODUCT & SERVICE SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2027

4.3 MULTIPLEX ASSAYS MARKET SHARE, BY TYPE, 2022 VS. 2027

FIGURE 16 PROTEIN MULTIPLEX ASSAYS TYPE SEGMENT TO ACCOUNT FOR

LARGEST MARKET SHARE

4.4 MULTIPLEX ASSAYS MARKET SHARE, BY TECHNOLOGY, 2022 VS. 2027

FIGURE 17 FLOW CYTOMETRY TECHNOLOGY TO ACCOUNT FOR LARGEST MARKET SHARE

4.5 MULTIPLEX ASSAYS MARKET SHARE, BY APPLICATION, 2022 VS. 2027

FIGURE 18 RESEARCH & DEVELOPMENT APPLICATION TO ACCOUNT FOR LARGER MARKET SHARE

4.6 MULTIPLEX ASSAYS MARKET SHARE, BY END USER, 2022 VS. 2027

FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES END USER SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE

4.7 MULTIPLEX ASSAYS MARKET: REGIONAL GROWTH OPPORTUNITIES

FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 21 MULTIPLEX ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.2.1 DRIVERS

5.2.1.1 Increasing use of multiplex assays in companion diagnostics

5.2.1.2 Increasing advantages over singleplex and traditional assays

5.2.1.3 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis

FIGURE 22 INCIDENCE OF DIABETES, BY REGION, IN 2021, 2030, AND 2045

TABLE 1 TOTAL HEALTH EXPENDITURE DUE TO DIABETES (20–79 YEARS) IN 2021, BY COUNTRY

TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES

TABLE 3 APPROVED AND LAUNCHED MULTIPLEX ASSAYS FOR DIAGNOSIS OF SARS-COV-2

5.2.2 RESTRAINTS

5.2.2.1 Rising costs of equipment

5.2.2.2 Growing number of stringent regulations and standards

5.2.3 OPPORTUNITIES

5.2.3.1 Increasing validation of biomarkers in molecular and protein diagnostics

5.2.3.2 Rising need for high-throughput and automated systems

5.2.4 CHALLENGES

5.2.4.1 Increasing dearth of skilled professionals

TABLE 4 NUMBER OF LAB TECHNOLOGISTS AND TECHNICIANS IN US, 2020

5.3 CUSTOMIZATION DATA

TABLE 5 MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

6 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE

6.1 INTRODUCTION

TABLE 6 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

6.2 PRIMARY NOTES

6.2.1 KEY INDUSTRY INSIGHTS

6.3 CONSUMABLES

6.3.1 RECURRENT REQUIREMENTS AND PURCHASES OF CONSUMABLES TO DRIVE MARKET

TABLE 7 MULTIPLEX ASSAY CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 8 NORTH AMERICA: MULTIPLEX ASSAY CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

6.4 INSTRUMENTS

6.4.1 LAUNCH OF TECHNOLOGICALLY ADVANCED INSTRUMENTS TO SUPPORT MARKET GROWTH

TABLE 9 MULTIPLEX ASSAY INSTRUMENT MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 10 NORTH AMERICA: MULTIPLEX ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

6.5 SOFTWARE & SERVICES

6.5.1 INCREASING NEED FOR EFFECTIVE DATA MANAGEMENT WITHIN LABORATORIES TO FUEL UPTAKE OF ADVANCED SOFTWARE

TABLE 11 MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 12 NORTH AMERICA: MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7 MULTIPLEX ASSAYS MARKET, BY TYPE

7.1 INTRODUCTION

TABLE 13 MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

7.2 PROTEIN MULTIPLEX ASSAYS

TABLE 14 PROTEIN MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 15 PROTEIN MULTIPLEX ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 16 NORTH AMERICA: PROTEIN MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7.2.1 PLANAR PROTEIN ASSAYS

7.2.1.1 Pivotal role in drug discovery to support uptake

TABLE 17 PLANAR PROTEIN ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 18 NORTH AMERICA: PLANAR PROTEIN ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7.2.2 BEAD-BASED PROTEIN ASSAYS

7.2.2.1 Best suited to study protein-protein interactions

TABLE 19 BEAD-BASED PROTEIN ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 20 NORTH AMERICA: BEAD-BASED PROTEIN ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7.2.3 OTHER PROTEIN ASSAYS

TABLE 21 OTHER PROTEIN ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 22 NORTH AMERICA: OTHER PROTEIN ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7.3 NUCLEIC ACID MULTIPLEX ASSAYS

TABLE 23 SOME FDA-AUTHORIZED MULTIPLEX ASSAYS AND INSTRUMENTS FOR SIMULTANEOUS DETECTION OF INFLUENZA AND SARS-COV-2

TABLE 24 NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 25 NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 26 NORTH AMERICA: NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7.3.1 PLANAR NUCLEIC ACID ASSAYS

7.3.1.1 Planar multiplex assays preferred in gene expression analysis, SNP genotyping, and transcriptome analysis

TABLE 27 PLANAR NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 28 NORTH AMERICA: PLANAR NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7.3.2 BEAD-BASED NUCLEIC ACID ASSAYS

7.3.2.1 Increasing infectious diseases and genetic screening tests to drive market

TABLE 29 BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 30 NORTH AMERICA: BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7.3.3 OTHER NUCLEIC ACID ASSAYS

TABLE 31 OTHER NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 32 NORTH AMERICA: OTHER NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7.4 CELL-BASED MULTIPLEX ASSAYS

7.4.1 BETTER VARIABILITY THAN BIOCHEMICAL-BASED ASSAYS TO DRIVE MARKET

TABLE 33 CELL-BASED MULTIPLEX ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 34 NORTH AMERICA: CELL-BASED MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

8 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY

8.1 INTRODUCTION

TABLE 35 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

8.2 FLOW CYTOMETRY

8.2.1 WIDE APPLICATIONS IN PROTEIN EXPRESSION, RNA, AND CELL HEALTH STATUS TO MAKE THIS MARKET SEGMENT LARGEST

TABLE 36 MULTIPLEX ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION, 2020–2027 (USD MILLION)

TABLE 37 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2020–2027 (USD MILLION)

8.3 FLUORESCENCE DETECTION

8.3.1 INCREASING USE OF MICROARRAY SCANNERS AND FLUORESCENCE MICROSCOPES TO FUEL GROWTH

TABLE 38 MULTIPLEX ASSAYS MARKET FOR FLUORESCENCE DETECTION, BY REGION, 2020–2027 (USD MILLION)

TABLE 39 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2020–2027 (USD MILLION)

8.4 LUMINESCENCE

8.4.1 RAPID AND EASY-TO-USE BENEFITS OF LUMINESCENCE TECHNOLOGY TO DRIVE MARKET

TABLE 40 MULTIPLEX ASSAYS MARKET FOR LUMINESCENCE, BY REGION, 2020–2027 (USD MILLION)

TABLE 41 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR LUMINESCENCE, BY COUNTRY, 2020–2027 (USD MILLION)

8.5 MULTIPLEX REAL-TIME PCR

8.5.1 HIGH SPECIFICITY AND SENSITIVITY OF MULTIPLEX REAL-TIME PCR TO DRIVE ADOPTION OF MULTIPLEX ASSAYS

TABLE 42 MULTIPLEX ASSAYS MARKET FOR MULTIPLEX REAL-TIME PCR, BY REGION, 2020–2027 (USD MILLION)

TABLE 43 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2020–2027 (USD MILLION)

8.6 OTHER TECHNOLOGIES

TABLE 44 MULTIPLEX ASSAYS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)

TABLE 45 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)

9 MULTIPLEX ASSAYS MARKET, BY APPLICATION

9.1 INTRODUCTION

TABLE 46 MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

9.2 RESEARCH & DEVELOPMENT

TABLE 47 MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)

TABLE 48 MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION)

TABLE 49 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)

9.2.1 DRUG DISCOVERY & DEVELOPMENT

9.2.1.1 Multiplex assays massively employed in preclinical and clinical phases

TABLE 50 MULTIPLEX ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION)

TABLE 51 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)

9.2.2 BIOMARKER DISCOVERY & VALIDATION

9.2.2.1 Multiplex assays aid in quantitative measurement of protein biomarkers in

large samples

TABLE 52 MULTIPLEX ASSAYS MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY REGION, 2020–2027 (USD MILLION)

TABLE 53 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2020–2027 (USD MILLION)

9.3 CLINICAL DIAGNOSTICS

TABLE 54 MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION)

TABLE 55 MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)

TABLE 56 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)

9.3.1 INFECTIOUS DISEASES

9.3.1.1 Growing prevalence of infectious diseases to drive uptake of multiplex assays

TABLE 57 MULTIPLEX ASSAYS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)

TABLE 58 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)

9.3.2 CANCER

9.3.2.1 Rising burden of cancer to drive market

TABLE 59 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)

TABLE 60 NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020, BY TYPE OF CANCER

TABLE 61 MULTIPLEX ASSAYS MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)

TABLE 62 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)

9.3.3 CARDIOVASCULAR DISEASES

9.3.3.1 High burden of cardiovascular diseases to support market growth

TABLE 63 MULTIPLEX ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION)

TABLE 64 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)

9.3.4 AUTOIMMUNE DISEASES

9.3.4.1 High incidence and prevalence of autoimmune diseases to drive demand for measures promoting early diagnosis

TABLE 65 PREVALENCE OF SOME AUTOIMMUNE DISEASES

TABLE 66 MULTIPLEX ASSAYS MARKET FOR AUTOIMMUNE DISEASES, BY

REGION, 2020–2027 (USD MILLION)

TABLE 67 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)

9.3.5 NERVOUS SYSTEM DISORDERS

9.3.5.1 Growing prevalence of nervous system disorders to fuel uptake of multiplex assays for early diagnosis and treatment

TABLE 68 MULTIPLEX ASSAYS MARKET FOR NERVOUS SYSTEM DISORDERS, BY REGION, 2020–2027 (USD MILLION)

TABLE 69 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)

9.3.6 METABOLISM & ENDOCRINOLOGY DISORDERS

9.3.6.1 Multiplex assays used to measure endocrine and metabolic biomarkers that help in timely diagnosis of such conditions

TABLE 70 MULTIPLEX ASSAYS MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY REGION, 2020–2027 (USD MILLION)

TABLE 71 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)

9.3.7 OTHER DISEASES

TABLE 72 MULTIPLEX ASSAYS MARKET FOR OTHER DISEASES, BY REGION, 2020–2027 (USD MILLION)

TABLE 73 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)

10 MULTIPLEX ASSAYS MARKET, BY END USER

10.1 INTRODUCTION

TABLE 74 MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)

10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

10.2.1 GROWING DEMAND FOR MULTIPLEX ASSAYS IN DRUG DISCOVERY & CLINICAL STUDIES TO DRIVE ITS UPTAKE

TABLE 75 MULTIPLEX ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)

TABLE 76 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)

10.3 HOSPITALS & RESEARCH INSTITUTES

10.3.1 INCREASING NUMBER OF HOSPITALS TO DRIVE MARKET

TABLE 77 MULTIPLEX ASSAYS MARKET FOR HOSPITALS & RESEARCH

INSTITUTES, BY REGION, 2020–2027 (USD MILLION)

TABLE 78 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR HOSPITALS & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)

10.4 REFERENCE LABORATORIES

10.4.1 GROWING NUMBER OF CLINICAL TESTS PERFORMED IN REFERENCE LABORATORIES AND INCREASING NUMBER OF ACCREDITED LABORATORIES TO SUPPORT MARKET GROWTH

TABLE 79 MULTIPLEX ASSAYS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020–2027 (USD MILLION)

TABLE 80 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)

10.5 OTHER END USERS

TABLE 81 MULTIPLEX ASSAYS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)

TABLE 82 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)

11 MULTIPLEX ASSAYS MARKET, BY REGION

11.1 INTRODUCTION

TABLE 83 MULTIPLEX ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)

11.2 NORTH AMERICA

TABLE 84 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 85 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 86 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 87 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 88 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 89 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)

FIGURE 23 NORTH AMERICA: MULTIPLEX ASSAYS MARKET SNAPSHOT

11.2.1 RECESSION IMPACT ON NORTH AMERICA

11.2.2 US

11.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market

TABLE 90 US: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE,

2020–2027 (USD MILLION)

TABLE 91 US: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 92 US: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 93 US: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 94 US: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)

11.2.3 CANADA

11.2.3.1 Increased funding activities by government in life sciences research & drug development to support market growth

TABLE 95 CANADA: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 96 CANADA: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 97 CANADA: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 98 CANADA: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 99 CANADA: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)

11.3 EUROPE

TABLE 100 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP)

TABLE 101 EUROPE: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 102 EUROPE: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 103 EUROPE: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 104 EUROPE: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 105 EUROPE: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)

11.3.1 RECESSION IMPACT ON EUROPE

11.4 ASIA PACIFIC

FIGURE 24 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET SNAPSHOT

TABLE 106 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 107 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027

(USD MILLION)

TABLE 108 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 109 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 110 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)

11.4.1 RECESSION IMPACT ON ASIA PACIFIC

11.5 REST OF THE WORLD

TABLE 111 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 112 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 113 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 114 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 115 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)

11.5.1 RECESSION IMPACT ON REST OF THE WORLD

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW

12.2 STRATEGIES ADOPTED BY KEY PLAYERS

12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS

TABLE 116 OVERVIEW OF STRATEGIES ADOPTED BY KEY COMPANIES

12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS

FIGURE 25 REVENUE SHARE ANALYSIS OF TOP PLAYERS (2017–2021)

12.4 MARKET SHARE ANALYSIS

12.4.1 MULTIPLEX ASSAYS MARKET

FIGURE 26 MULTIPLEX ASSAYS MARKET SHARE, BY KEY PLAYER, 2021

TABLE 117 MULTIPLEX ASSAYS MARKET: INTENSITY OF COMPETITIVE RIVALRY

12.5 COMPANY EVALUATION QUADRANT

12.5.1 LIST OF EVALUATED VENDORS

12.5.2 STARS

12.5.3 EMERGING LEADERS

12.5.4 PERVASIVE PLAYERS

12.5.5 PARTICIPANTS

FIGURE 27 MULTIPLEX ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021

12.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021)

12.6.1 PROGRESSIVE COMPANIES

12.6.2 STARTING BLOCKS

12.6.3 RESPONSIVE COMPANIES

12.6.4 DYNAMIC COMPANIES

FIGURE 28 MULTIPLEX ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021

12.7 COMPETITIVE SCENARIO

12.7.1 PRODUCT LAUNCHES & REGULATORY APPROVALS

TABLE 118 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS (2020- 2023)

12.7.2 DEALS

TABLE 119 KEY DEALS (2020-2023)

13 COMPANY PROFILES

13.1 KEY PLAYERS

(Business Overview, Products Offered, Recent Developments, and MnM View)*

13.1.1 ILLUMINA, INC.

TABLE 120 ILLUMINA, INC.: BUSINESS OVERVIEW

FIGURE 29 COMPANY SNAPSHOT: ILLUMINA, INC. (2022)

13.1.2 BIO-RAD LABORATORIES, INC.

TABLE 121 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW

FIGURE 30 COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC. (2022)

13.1.3 THERMO FISHER SCIENTIFIC, INC.

TABLE 122 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW

FIGURE 31 COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC, INC. (2021)

13.1.4 BECTON, DICKINSON AND COMPANY

TABLE 123 BECTON, DICKINSON AND COMPANY.: BUSINESS OVERVIEW

FIGURE 32 COMPANY SNAPSHOT: BECTON, DICKINSON AND COMPANY (2022)

13.1.5 DIASORIN S.P.A.

TABLE 124 DIASORIN S.P.A.: BUSINESS OVERVIEW

FIGURE 33 COMPANY SNAPSHOT: DIASORIN S.P.A. (2021)

13.1.6 QIAGEN N.V.

TABLE 125 QIAGEN N.V.: BUSINESS OVERVIEW

FIGURE 34 COMPANY SNAPSHOT: QIAGEN N.V. (2021)

13.1.7 ABCAM PLC

TABLE 126 ABCAM PLC.: BUSINESS OVERVIEW

FIGURE 35 COMPANY SNAPSHOT: ABCAM PLC (2021)

13.1.8 MERCK KGAA

TABLE 127 MERCK KGAA: BUSINESS OVERVIEW

FIGURE 36 COMPANY SNAPSHOT: MERCK KGAA (2022)

13.1.9 AGILENT TECHNOLOGIES, INC.

TABLE 128 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW

FIGURE 37 COMPANY SNAPSHOT: AGILENT TECHNOLOGIES, INC. (2022)

13.1.10 QUANTERIX

TABLE 129 QUANTERIX: BUSINESS OVERVIEW

FIGURE 38 COMPANY SNAPSHOT: QUANTERIX (2022)

13.1.11 BIO-TECHNE

TABLE 130 BIO-TECHNE: BUSINESS OVERVIEW

FIGURE 39 COMPANY SNAPSHOT: BIO-TECHNE (2021)

13.1.12 MESO SCALE DIAGNOSTICS, LLC

TABLE 131 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW

13.1.13 RANDOX LABORATORIES LTD.

TABLE 132 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW

* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.

13.2 OTHER PLAYERS

13.2.1 OLINK

TABLE 133 OLINK: COMPANY OVERVIEW

13.2.2 SEEGENE INC.

TABLE 134 SEEGENE INC.: COMPANY OVERVIEW

13.2.3 SIEMENS HEALTHINEERS AG

TABLE 135 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW

13.2.4 PERKINELMER INC.

TABLE 136 PERKINELMER INC.: COMPANY OVERVIEW

13.2.5 SHIMADZU CORPORATION

TABLE 137 SHIMADZU CORPORATION: COMPANY OVERVIEW

13.2.6 PROMEGA CORPORATION

TABLE 138 PROMEGA CORPORATION: COMPANY OVERVIEW

13.2.7 ENZO BIOCHEM INC.

TABLE 139 ENZO BIOCHEM INC.: COMPANY OVERVIEW

13.2.8 CAYMAN CHEMICAL

TABLE 140 CAYMAN CHEMICAL: COMPANY OVERVIEW

13.2.9 BOSTER BIOLOGICAL TECHNOLOGY

TABLE 141 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW

13.2.10 ANTIGENIX AMERICA, INC.

TABLE 142 ANTIGENIX AMERICA, INC.: COMPANY OVERVIEW

13.2.11 QUANSYS BIOSCIENCES INC.

TABLE 143 QUANSYS BIOSCIENCES INC.: COMPANY OVERVIEW

13.2.12 RAYBIOTECH LIFE, INC.

TABLE 144 RAYBIOTECH LIFE, INC.: COMPANY OVERVIEW

14 APPENDIX

14.1 DISCUSSION GUIDE

14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL

14.3 CUSTOMIZATION OPTIONS

14.4 RELATED REPORTS

14.5 AUTHOR DETAILS

I would like to order

Product name: Multiplex Assays Market by Product & Service (Consumables, Instruments, Software & Services), Type (Nucleic Acid, Protein), Technology (Flow Cytometry, Luminescence), Application (R&D, Diagnosis), End User (Pharma, Hospitals) - Global Forecast to 2027

Product link: <https://marketpublishers.com/r/MF6BEECD290EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MF6BEECD290EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970